DAPAGLIFLOZIN, Zibotentan + Dapagliflozin, Zibotentan + Dapagliflozin
D4325C00010
Phase 3 small_molecule active
Quick answer
DAPAGLIFLOZIN, Zibotentan + Dapagliflozin, Zibotentan + Dapagliflozin for Chronic Kidney Disease and High Proteinuria is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Chronic Kidney Disease and High Proteinuria
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active